Tazemetostat Hydrobromide Tablet shortage
To Be DiscontinuedTazemetostat Hydrobromide Tablet is currently listed as To Be Discontinued in the FDA Drug Shortage Database. Reported reason: Not specified.
Therapeutic category
Dosage form
Tablet
Routes
ORAL
Last updated
03/27/2026
Strength variants
- Not specified
Need sourcing help for Tazemetostat Hydrobromide Tablet?
Get connected with licensed distributors and 503B compounders that can fulfill orders during active shortages. Verified suppliers, no spam.
Connect with a sourcing partnerManufacturers reporting shortage
- Epizyme, Inc. (An Ipsen Company)(855)-463-5127To Be Discontinued
Reason for shortage
ad slot 300x250
Related shortages in Oncology
Azacitidine Injection
- Category
- Oncology
- Reason
- Demand increase for the drug
- Updated
- 04/08/2026
Azacitidine Injection
- Category
- Oncology
- Reason
- Not specified
- Updated
- 04/07/2026
Azacitidine Injection
- Category
- Oncology
- Reason
- Not specified
- Updated
- 04/03/2026
Carboplatin Injection
- Category
- Oncology
- Reason
- Delay in shipping of the drug
- Updated
- 04/02/2026
Carboplatin Injection
- Category
- Oncology
- Reason
- Discontinuation of the manufacture of the drug
- Updated
- 04/02/2026
Carboplatin Injection
- Category
- Oncology
- Reason
- Discontinuation of the manufacture of the drug
- Updated
- 04/02/2026
This information is not medical advice. Consult your pharmacist. Data is sourced from the FDA Drug Shortage Database and may not reflect real-time inventory at your facility. ShortageWatch is independent and not affiliated with the FDA.